Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry

Multiple Sclerosis Journal

Volumn 17, Issue 7, 2011, Pages 838-850

  Teunissen, C E ^a   Koel Simmelink, Mja ^a   Pham, T V ^a   Knol, J C ^a   Khalil, M ^a,b   Trentini, A ^a,c   Killestein, J ^a   Nielsen, J ^a   Vrenken, H ^a   Popescu, V ^a   Dijkstra, C D ^a   Jimenez, C R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

biomarkers; cerebrospinal fluid; diagnosis; multiple sclerosis; progression; proteomics; serum

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; ION; PEPTIDE; SECRETOGRANIN II;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ATROPHY; BLOOD LEVEL; BODY FLUID; BRAIN ATROPHY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROL GROUP; DISEASE COURSE; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PEPTIDE ANALYSIS; RATING SCALE; RELAPSE;

EID: 79959504808     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511399614     Document Type: Article

References (37)

1. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005 ; 4: 32-41 (Pubitemid 40023234)
2. Teunissen CE, Killestein J, Giovannoni G. Biomarker research in MS: addressing axonal damage and heterogeneity. Biomark Med. 2007 ; 1: 111-119
3. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
4. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006 ; 13: 913-922 (Pubitemid 44284895)
5. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
6. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med. 2009 ; 13: 1586-1603
7. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler. 2004 ; 10: 245-260 (Pubitemid 38807450)
8. Lehmensiek V, Sussmuth SD, Tauscher G, Brettschneider J, Felk S, Gillardon F, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler. 2007 ; 13: 840-849 (Pubitemid 351540854)
9. Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010 ; 73: 1117-1132
10. Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009 ; 452: 214-217
11. Mattsson N, Ruetschi U, Podust VN, Stridsberg M, Li S, Andersen O, et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem. 2007 ; 103: 1932-1939 (Pubitemid 350126644)
12. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, Luider TM, et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics. 2008 ; 8: 1576-1585 (Pubitemid 351580204)
13. Stoop MP, Dekker LJ, Titulaer MK, Lamers RJ, Burgers PC, Sillevis Smitt PA, et al. Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple sclerosis-related proteins. J Proteome Res. 2009 ; 8: 1404-1414
14. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics. 2006 ; 5: 1840-1852 (Pubitemid 44688193)
15. Jimenez CR, Koel-Simmelink MJR, Pham T, Voort van der L, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry. Proteomics Clin Appl. 2007 ; 1: 1385-1392
16. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002 ; 125: 1676-1695
17. De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. 2007 ; 17 (Suppl. 1). 10S - 15S (Pubitemid 46558262)
18. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand. 2010 ; 122: 1-8
19. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 ; 73: 1914-1922
20. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
23. Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci. 2009 ; 7: 34-34
24. Pham TV, van de Wiel MA, Jimenez CR. Support vector machine approach to separate control and breast cancer serum samples. Stat Appl Genet Mol Biol. 2008 ; 7: Article 11 - Article 11
25. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002 ; 17: 479-489
26. Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, et al. Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics. 2010 ; 10: 81-89
27. Ritchie RF. A simple, direct, and sensitive technique for measurement of specific protein in dilute solution. J Lab Clin Med. 1967 ; 70: 512-517
28. Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C, et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res. 2008 ; 7: 386-399 (Pubitemid 351171153)
29. Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol. 2009 ; 155: 128-139
30. Kaneshiro N, Xiang Y, Nagai K, Kurokawa MS, Okamoto K, Arito M, et al. Comprehensive analysis of short peptides in sera from patients with IgA nephropathy. Rapid Commun Mass Spectrom. 2009 ; 23: 3720-3728
31. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res. 2003 ; 2: 361-372 (Pubitemid 36988415)
32. Jimenez CR, Piersma S, Pham TV. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. Biomark Med. 2007 ; 1: 541-565
33. Fabriek BO, Moller HJ, Vloet RP, van Winsen LM, Hanemaaijer R, Teunissen CE, et al. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol. 2007 ; 187: 179-186 (Pubitemid 47001547)
34. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 1999 ; 122: 191-197 (Pubitemid 29067202)
35. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999 ; 53: 1397-1401 (Pubitemid 29491927)
36. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003 ; 348: 1134-1149 (Pubitemid 36337325)
37. Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007 ; 204: 571-582 (Pubitemid 46457080)